Vanguard Group Inc Immunome Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Immunome Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,921,212 shares of IMNM stock, worth $33.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,921,212

Previous 2,019,738 44.63%

Holding current value

$33.9 Million

Previous $49.8 Million 29.09%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$11.54 - $22.11 $10.4 Million - $19.9 Million	901,474 Added 44.63%	2,921,212 $35.3 Million
Q1 2024 May 10, 2024	BUY	$11.01 - $27.34 $3.08 Million - $7.65 Million	279,712 Added 16.08%	2,019,738 $49.8 Million
Q4 2023 Feb 14, 2024	BUY	$7.3 - $10.73 $9.81 Million - $14.4 Million	1,343,697 Added 339.04%	1,740,026 $18.6 Million
Q3 2023 Nov 14, 2023	BUY	$6.17 - $9.16 $138,522 - $205,651	22,451 Added 6.0%	396,329 $3.31 Million
Q4 2022 Feb 10, 2023	BUY	$2.21 - $5.0 $426 - $965	193 Added 0.05%	373,878 $826,000
Q3 2022 Nov 14, 2022	BUY	$3.39 - $6.14 $10,675 - $19,334	3,149 Added 0.85%	373,685 $1.66 Million
Q1 2022 May 13, 2022	SELL	$3.88 - $13.99 $22,589 - $81,449	-5,822 Reduced 1.55%	370,536 $2.11 Million
Q4 2021 Feb 14, 2022	BUY	$12.96 - $23.44 $50,258 - $90,900	3,878 Added 1.04%	376,358 $4.88 Million
Q3 2021 Nov 12, 2021	BUY	$12.5 - $27.76 $879,850 - $1.95 Million	70,388 Added 23.3%	372,480 $9.07 Million
Q2 2021 Aug 13, 2021	BUY	$16.33 - $32.33 $4.93 Million - $9.77 Million	302,092 New	302,092 $5.23 Million

Others Institutions Holding IMNM

# of Institutions

118

Shares Held

43.5M

Call Options Held

67.2K

Put Options Held

65.9K

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $141M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Immunome Inc. Transaction History